CX11 / Wingtech Pharma, CORXEL - LARVOL DELTA

A Phase Ia Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Single Ascending Doses of VCT220 Tablets in Chinese Healthy Subjects, and the Effect of Food on its Pharmacokinetic Profile (ChiCTR) - P1 | N=72 | Completed | Sponsor: West China Second University Hospital of Sichuan University; West China Second University Hospital of Sichuan University (WCSUH- SCU)

New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

This is an Open-label, Non-randomized Study to Assess the Pharmacokinetics (PK) of VCT220 in Healthy Volunteers When Administered With Rifampin or Itraconazole (clinicaltrials.gov) - P1 | N=32 | Active, not recruiting | Sponsor: Vincentage Pharma Co., Ltd | Not yet recruiting ➔ Active, not recruiting

Enrollment closed • Genetic Disorders • Obesity

A Drug Drug Interaction Study to Evaluate the Effect of VCT220 on the Pharmacokinetics of Repaglinide, Rosuvastatin, and Digoxin in Healthy, Overweight, and Obese Subjects (clinicaltrials.gov) - P1 | N=24 | Active, not recruiting | Sponsor: Vincentage Pharma Co., Ltd | Recruiting ➔ Active, not recruiting

Enrollment closed • Genetic Disorders • Obesity

A Pharmacokinetic Study of VCT220 in Particicants With Hepatic Injury and Normal Hepatic Function (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: Vincentage Pharma Co., Ltd | Not yet recruiting ➔ Completed

Trial completion • Genetic Disorders • Hepatology • Liver Failure • Obesity

A Study to Evaluate the Efficacy and Safety of CX11 Tablets in Overweight/Obese Participants (clinicaltrials.gov) - P2 | N=250 | Active, not recruiting | Sponsor: Corxel Pharmaceuticals | Enrolling by invitation ➔ Active, not recruiting

Enrollment closed • Genetic Disorders • Obesity

A Drug Drug Interaction Study to Evaluate the Effect of VCT220 on the Pharmacokinetics of Repaglinide, Rosuvastatin, and Digoxin in Healthy, Overweight, and Obese Subjects (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Vincentage Pharma Co., Ltd

New P1 trial • Genetic Disorders • Obesity

This is an Open-label, Non-randomized Study to Assess the Pharmacokinetics (PK) of VCT220 in Healthy Volunteers When Administered With Rifampin or Itraconazole (clinicaltrials.gov) - P1 | N=32 | Not yet recruiting | Sponsor: Vincentage Pharma Co., Ltd

New P1 trial • Genetic Disorders • Obesity

A Study to Evaluate the Efficacy and Safety of CX11 Tablets in Overweight/Obese Participants (clinicaltrials.gov) - P2 | N=250 | Enrolling by invitation | Sponsor: Corxel Pharmaceuticals | Not yet recruiting ➔ Enrolling by invitation

Enrollment open • Genetic Disorders • Obesity

Efficacy and Safety of VCT220 in Chinese Adults with Overweight or Obesity (ADA 2025) - "This study showed VCT220 was safe and led to robust and clinically meaningful BW reduction and improvements in cardiac risk factors including BP and WC. These findings support further development of VCT220 as a oral treatment option for weight management."

Clinical • Metabolic Disorders • Obesity

Chengdu Wentai Pharmaceutical Technology Co., Ltd.'s application for implied license for clinical trials of drugs has been accepted [Google translation] (163.com) - "On June 20, according to the official website of CDE, Chengdu Wentai Pharmaceutical Technology Co., Ltd. jointly applied for the drug 'VCT220 Tablets' and obtained implicit approval for clinical trials, acceptance number CXHL2500353....Public information shows that the indications of the drug 'VCT220 Tablets' are: This product is intended to be used for blood pressure control in hypertensive patients with overweight/obesity."

New trial • Obesity

CX11/VCT220 China Phase 2 Clinical Trial Data Results Announced at the 2025 American Diabetes Association (ADA) Conference [Google translation] (163.com) - P2 | N=250 | NCT07011797 | Sponsor: Corxel Pharmaceuticals | "The mean baseline weight of the enrolled subjects was 91.76 kg, the mean BMI was 32.03 kg/m², and 93.6% of the subjects had a BMI greater than or equal to 28 kg/m². At week 16 of treatment, the mean percentage change in body weight from baseline ranged from -5.8% to -9.7% in the CX11/VCT220 dose groups, and -1.6% in the placebo group. The weight loss effect of all CX11/VCT220 dose groups was significantly better than that of the placebo group. In the CX11/VCT220 treatment group, 55%-90% of the subjects achieved at least 5% weight loss at week 16, while the placebo group achieved the target rate of only 13%. Patients treated with CX11/VCT220 showed improvements in all measured weight-related and cardiometabolic indicators, including liver enzymes (ALT, AST) and blood pressure."

P2 data • Obesity

A Study to Evaluate the Efficacy and Safety of CX11 Tablets in Overweight/Obese Participants (clinicaltrials.gov) - P2 | N=250 | Not yet recruiting | Sponsor: Corxel Pharmaceuticals

New P2 trial • Genetic Disorders • Obesity

A Pharmacokinetic Study of VCT220 in Particicants With Hepatic Injury and Normal Hepatic Function (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Vincentage Pharma Co., Ltd

New P1 trial • Genetic Disorders • Hepatology • Liver Failure • Obesity

A Research Study of VCT220 in Adult Chinese Participants With Obesity (clinicaltrials.gov) - P3 | N=840 | Active, not recruiting | Sponsor: Vincentage Pharma Co., Ltd

New P3 trial • Genetic Disorders • Obesity

CORXEL Receives Study May Proceed Letter from the U.S. FDA for the Phase 2 Trial of CX11 in Patients with Obesity and Overweight Conditions (GlobeNewswire) - "Corxel Pharmaceuticals Limited...announced the clearance of an investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA) for a U.S. Phase 2 trial of CX11, an investigational oral once-daily small molecule glucagon-like peptide-1 receptor agonist (GLP-1 RA). This randomized, double-blind, placebo-controlled trial will evaluate the efficacy and safety of CX11 in patients with obesity and overweight conditions in the U.S., with enrollment expected to begin in the second quarter of 2025."

IND • New P2 trial • Obesity

CORXEL Acquires Worldwide (excluding Greater China) Rights to an Oral Small Molecule GLP-1 RA for the Treatment of Obesity and Diabetes (GlobeNewswire) - "Corxel Pharmaceuticals...today announced the acquisition of CX11 (also known as VCT220), an oral small molecule glucagon-like peptide-1 receptor agonist (GLP-1 RA), for worldwide (excluding Greater China) development and commercialization, from Vincentage...CORXEL plans to initiate a global (excluding Greater China) Phase 2 study in obese and overweight patients in 2025."

Licensing / partnership • New P2 trial • Diabetes • Obesity

A Study to Evaluate the Efficacy and Safety of VCT220 in Obesity Chinese Population (clinicaltrials.gov) - P2 | N=250 | Completed | Sponsor: Vincentage Pharma Co., Ltd

New P2 trial • Genetic Disorders • Obesity